Fredun Pharmaceuticals acquires Furlicks to enter pet wellness market
- Fredun Pharmaceuticals acquires Furlicks from USV and Wellbeing Nutrition
- Entry into pet wellness market via differentiated oral-strip solutions
- Plans to launch 12 new SKUs in first phase, 32 in second phase
- Leverages existing manufacturing and distribution capabilities
*this image is generated using AI for illustrative purposes only.
Fredun Pharmaceuticals has acquired the Furlicks brand from USV and Wellbeing Nutrition, marking its strategic entry into the pet wellness market. The acquisition brings the brand's differentiated oral-strip solutions under Fredun Pharmaceuticals' umbrella.
Acquisition details
The deal sees Fredun Pharmaceuticals sourcing the Furlicks brand jointly from pharma major USV and its subsidiary Wellbeing Nutrition. This move represents a deliberate diversification into the growing pet wellness segment, allowing the company to leverage its established capabilities in manufacturing, product development, quality systems, R&D, supply chain, and distribution.
Furlicks focuses on convenient, easy-to-administer oral-strip solutions, offering an alternative to conventional pet supplements. Its existing portfolio spans key categories including skin and coat, gut health, joint care, calming, oral care, and multivitamins.
Product launch roadmap
As part of its initial rollout strategy, Fredun Pharmaceuticals plans to introduce 12 new SKUs in the first phase under the Furlicks brand. The company has aligned 32 new SKUs for launch in the second phase. Over time, the ambition is to evolve Furlicks from a differentiated oral-strip proposition into a broader everyday pet-wellness platform.
| Parameter | Details |
|---|---|
| Brand acquired | Furlicks |
| Acquired from | USV and Wellbeing Nutrition |
| Market segment | Pet wellness |
| First-phase SKUs planned | 12 |
| Second-phase SKUs aligned | 32 |
Strategic significance
The acquisition signals Fredun Pharmaceuticals' intent to expand beyond its existing pharmaceutical portfolio into the pet wellness space. By leveraging the established Furlicks brand, the company aims to establish a presence in a segment that sits at the intersection of animal health and consumer wellness.
Mr. Fredun Medhora, MD & CFO of Fredun Pharmaceuticals Ltd., stated that the brand is more than an addition to the portfolio; it is a differentiated platform with the potential to build a significant pet-wellness business. He noted that combining Furlicks' innovation with Fredun's manufacturing capabilities aims to make quality pet care more accessible across India.
Historical Stock Returns for Fredun Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.35% | -5.11% | 0.0% | 0.0% | 0.0% | 0.0% |
How will Fredun Pharmaceuticals leverage its existing pharmaceutical distribution network to gain market share against established pet care giants in India?
What is the projected timeline and investment required to scale the Furlicks brand from a niche oral-strip provider to a comprehensive everyday pet-wellness platform?
How might this acquisition impact Fredun Pharmaceuticals' revenue mix and profit margins in the medium term compared to its core pharma business?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
